Prefrontal cortical circuits in schizophrenia.
暂无分享,去创建一个
[1] Takanori Hashimoto,et al. Protracted Developmental Trajectories of GABA A Receptor α1 and α2 Subunit Expression in Primate Prefrontal Cortex , 2009, Biological Psychiatry.
[2] K. Deisseroth,et al. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance , 2009, Nature.
[3] M. Rasband,et al. Postnatal development of synaptic structure proteins in pyramidal neuron axon initial segments in monkey prefrontal cortex , 2009, The Journal of comparative neurology.
[4] G. Sugranyes,et al. Cannabis use and age of diagnosis of schizophrenia , 2009, European Psychiatry.
[5] D. Lewis,et al. Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. , 2009, The Journal of clinical investigation.
[6] B. Alger,et al. Synaptic Cross Talk between Perisomatic-Targeting Interneuron Classes Expressing Cholecystokinin and Parvalbumin in Hippocampus , 2009, The Journal of Neuroscience.
[7] David A. Lewis,et al. Selective Alterations in Postsynaptic Markers of Chandelier Cell Inputs to Cortical Pyramidal Neurons in Subjects with Schizophrenia , 2009, Neuropsychopharmacology.
[8] R. Cho,et al. Tiagabine Increases [11C]flumazenil Binding in Cortical Brain Regions in Healthy Control Subjects , 2009, Neuropsychopharmacology.
[9] Ekaterina A. Placzek,et al. Membrane microdomains and metabolic pathways that define anandamide and 2-arachidonyl glycerol biosynthesis and breakdown , 2008, Neuropharmacology.
[10] Sarah E. Forster,et al. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. , 2008, The American journal of psychiatry.
[11] Peter B. Jones,et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review , 2008, British Journal of Psychiatry.
[12] D. Lewis,et al. GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. , 2008, Schizophrenia bulletin.
[13] P. Penzes,et al. Dendritic spine dynamics – a key role for kalirin-7 , 2008, Trends in Neurosciences.
[14] G. Tononi,et al. Reduced evoked gamma oscillations in the frontal cortex in schizophrenia patients: a TMS/EEG study. , 2008, American Journal of Psychiatry.
[15] David A Lewis,et al. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. , 2008, Archives of general psychiatry.
[16] E. P. Gardner,et al. Petilla terminology: nomenclature of features of GABAergic interneurons of the cerebral cortex , 2008, Nature Reviews Neuroscience.
[17] H. M. Morris,et al. Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder. , 2008, Cerebral cortex.
[18] M. McInnis,et al. Psychiatric genetics: progress amid controversy , 2008, Nature Reviews Genetics.
[19] R. Fields,et al. White matter in learning, cognition and psychiatric disorders , 2008, Trends in Neurosciences.
[20] D. Barch,et al. The Cognitive Neuroscience of Working Memory: Relevance to CNTRICS and Schizophrenia , 2008, Biological Psychiatry.
[21] D. Javitt,et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia , 2008, Trends in Neurosciences.
[22] M. Palkovits,et al. Regional distribution and effects of postmortal delay on endocannabinoid content of the human brain , 2008, Neuroscience.
[23] M. Rasband,et al. Spectrin and Ankyrin-Based Cytoskeletons at Polarized Domains in Myelinated Axons , 2008, Experimental biology and medicine.
[24] David A Lewis,et al. Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. , 2008, The American journal of psychiatry.
[25] A. Zaitsev,et al. Functional maturation of excitatory synapses in layer 3 pyramidal neurons during postnatal development of the primate prefrontal cortex. , 2008, Cerebral cortex.
[26] D. Dietrich,et al. The myelin-pathogenesis puzzle in schizophrenia: a literature review , 2008, Molecular Psychiatry.
[27] H. M. Morris,et al. Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia , 2008, Molecular Psychiatry.
[28] J. Callicott,et al. Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. , 2007, Cerebral cortex.
[29] S. Mosolov,et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial , 2007, Nature Medicine.
[30] Peter B. Jones,et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review , 2007, The Lancet.
[31] J. Lieberman,et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. , 2007, The American journal of psychiatry.
[32] Michael F. Green,et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. , 2007, Archives of general psychiatry.
[33] R. Drake,et al. Schizophrenia and co-occurring substance use disorder. , 2007, The American journal of psychiatry.
[34] J. Meador-Woodruff,et al. NMDA receptors and schizophrenia. , 2007, Current opinion in pharmacology.
[35] C. Carter,et al. Impairments in frontal cortical γ synchrony and cognitive control in schizophrenia , 2006, Proceedings of the National Academy of Sciences.
[36] W. Singer,et al. Neural Synchrony in Brain Disorders: Relevance for Cognitive Dysfunctions and Pathophysiology , 2006, Neuron.
[37] G. Fischbach. Schizophrenia: signals from the other side , 2006, Nature Medicine.
[38] Karin E. Borgmann-Winter,et al. Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia , 2006, Nature Medicine.
[39] T. Hashimoto,et al. Molecular mechanisms contributing to dendritic spine alterations in the prefrontal cortex of subjects with schizophrenia , 2006, Molecular Psychiatry.
[40] T. Freund,et al. Molecular Composition of the Endocannabinoid System at Glutamatergic Synapses , 2006, The Journal of Neuroscience.
[41] Masahiko Watanabe,et al. Localization of diacylglycerol lipase-alpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. , 2006, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[42] Masahiko Watanabe,et al. The CB1 Cannabinoid Receptor Is the Major Cannabinoid Receptor at Excitatory Presynaptic Sites in the Hippocampus and Cerebellum , 2006, The Journal of Neuroscience.
[43] S. Hutton,et al. Comorbid substance use and age at onset of schizophrenia , 2006, British Journal of Psychiatry.
[44] David A Lewis,et al. Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. , 2006, Cerebral cortex.
[45] R. Poulton,et al. Cannabis and psychosis , 2006, BMJ : British Medical Journal.
[46] S. Haber,et al. Prefrontal Cortical Projections to the Midbrain in Primates: Evidence for a Sparse Connection , 2006, Neuropsychopharmacology.
[47] M. Chee,et al. fMRI study of maintenance and manipulation processes within working memory in first-episode schizophrenia. , 2005, The American journal of psychiatry.
[48] Tyrone D. Cannon,et al. Dorsolateral prefrontal cortex activity during maintenance and manipulation of information in working memory in patients with schizophrenia. , 2005, Archives of general psychiatry.
[49] David A Lewis,et al. Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia. , 2005, The American journal of psychiatry.
[50] D. Lewis,et al. Cortical inhibitory neurons and schizophrenia , 2005, Nature Reviews Neuroscience.
[51] Ralitza Gueorguieva,et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction , 2005, Biological Psychiatry.
[52] Jonathan D. Cohen,et al. Specificity of prefrontal dysfunction and context processing deficits to schizophrenia in never-medicated patients with first-episode psychosis. , 2005, American Journal of Psychiatry.
[53] R. McCarley,et al. Neural synchrony indexes disordered perception and cognition in schizophrenia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[54] M. Pistis,et al. Prefrontal Cortex Stimulation Induces 2-Arachidonoyl-Glycerol-Mediated Suppression of Excitation in Dopamine Neurons , 2004, The Journal of Neuroscience.
[55] M. Egan,et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. , 2004, American journal of human genetics.
[56] Priscilla Wu,et al. Ankyrin-Based Subcellular Gradient of Neurofascin, an Immunoglobulin Family Protein, Directs GABAergic Innervation at Purkinje Axon Initial Segment , 2004, Cell.
[57] T. Freund,et al. Segregation of two endocannabinoid‐hydrolyzing enzymes into pre‐ and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala , 2004, The European journal of neuroscience.
[58] Paul J. Harrison,et al. Catechol-O-Methyltransferase Inhibition Improves Set-Shifting Performance and Elevates Stimulated Dopamine Release in the Rat Prefrontal Cortex , 2004, The Journal of Neuroscience.
[59] Ralitza Gueorguieva,et al. The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis , 2004, Neuropsychopharmacology.
[60] David A Lewis,et al. Cortical connections of the lateral mediodorsal thalamus in cynomolgus monkeys , 2004, The Journal of comparative neurology.
[61] A. Sampson,et al. Stereological analysis of the mediodorsal thalamic nucleus in schizophrenia: Volume, neuron number, and cell types , 2004, The Journal of comparative neurology.
[62] Patricia S. Goldman-Rakic,et al. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction , 2004, Psychopharmacology.
[63] Victor Vostrikov,et al. Pathology of layer V pyramidal neurons in the prefrontal cortex of patients with schizophrenia. , 2004, The American journal of psychiatry.
[64] R. Kahn,et al. Cannabis use and age at onset of schizophrenia. , 2004, The American journal of psychiatry.
[65] Bita Moghaddam,et al. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia , 2004, Psychopharmacology.
[66] Paul J. Harrison,et al. Catechol‐o‐methyltransferase (COMT) and proline dehydrogenase (PRODH) mRNAs in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and major depression , 2004, Synapse.
[67] M. Egan,et al. Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. , 2003, The American journal of psychiatry.
[68] Marc W Howard,et al. Gamma oscillations correlate with working memory load in humans. , 2003, Cerebral cortex.
[69] Miles A Whittington,et al. Interneuron Diversity series: Inhibitory interneurons and network oscillations in vitro , 2003, Trends in Neurosciences.
[70] William Byne,et al. Magnetic resonance imaging of mediodorsal, pulvinar, and centromedian nuclei of the thalamus in patients with schizophrenia. , 2003, Archives of general psychiatry.
[71] A. Sampson,et al. Gene Expression Deficits in a Subclass of GABA Neurons in the Prefrontal Cortex of Subjects with Schizophrenia , 2003, The Journal of Neuroscience.
[72] T. Freund,et al. Role of endogenous cannabinoids in synaptic signaling. , 2003, Physiological reviews.
[73] Marc Laruelle,et al. Dopamine Depletion and In Vivo Binding of PET D1 Receptor Radioligands: Implications for Imaging Studies in Schizophrenia , 2003, Neuropsychopharmacology.
[74] Daniel R Weinberger,et al. Catechol O-Methyltransferase (COMT) mRNA Expression in the Dorsolateral Prefrontal Cortex of Patients with Schizophrenia , 2003, Neuropsychopharmacology.
[75] Paul J. Harrison,et al. Low medial and lateral right pulvinar volumes in schizophrenia: a postmortem study. , 2003, The American journal of psychiatry.
[76] Peter Falkai,et al. Volumes of association thalamic nuclei in schizophrenia: a postmortem study , 2003, Schizophrenia Research.
[77] D. Manoach. Prefrontal cortex dysfunction during working memory performance in schizophrenia: reconciling discrepant findings , 2003, Schizophrenia Research.
[78] D. Yurgelun-Todd,et al. Early-onset cannabis use and cognitive deficits: what is the nature of the association? , 2003, Drug and alcohol dependence.
[79] M. Vreugdenhil,et al. Parvalbumin-deficiency facilitates repetitive IPSCs and gamma oscillations in the hippocampus. , 2003, Journal of neurophysiology.
[80] David A Lewis,et al. Reduced Pyramidal Cell Somal Volume in Auditory Association Cortex of Subjects with Schizophrenia , 2003, Neuropsychopharmacology.
[81] P. Somogyi,et al. Brain-state- and cell-type-specific firing of hippocampal interneurons in vivo , 2003, Nature.
[82] S. Sesack,et al. Selective prefrontal cortex inputs to dopamine cells: implications for schizophrenia , 2002, Physiology & Behavior.
[83] Glyn Lewis,et al. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study , 2002, BMJ : British Medical Journal.
[84] A. Sampson,et al. Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. , 2002, Cerebral cortex.
[85] T. Freund,et al. Brain monoglyceride lipase participating in endocannabinoid inactivation , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[86] G. Sedvall,et al. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. , 2002, The American journal of psychiatry.
[87] R. V. Van Heertum,et al. Prefrontal Dopamine D1 Receptors and Working Memory in Schizophrenia , 2002, The Journal of Neuroscience.
[88] Thomas Babor,et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. , 2002, JAMA.
[89] A. Lichtman,et al. Endocannabinoids in cognition and dependence. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.
[90] A. Sampson,et al. Decreased somal size of deep layer 3 pyramidal neurons in the prefrontal cortex of subjects with schizophrenia. , 2001, Archives of general psychiatry.
[91] J. Sweeney,et al. Thalamic volumes in patients with first-episode schizophrenia. , 2001, The American journal of psychiatry.
[92] K. N. Dudkin,et al. Neurophysiological Correlates of Delayed Visual Differentiation Tasks in Monkeys: the Effects of the Site of Intracortical Blockade of NMDA Receptors , 2001, Neuroscience and Behavioral Physiology.
[93] J. Cohen,et al. Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. , 2001, Archives of general psychiatry.
[94] German Barrionuevo,et al. Synaptic targets of the intrinsic axon collaterals of supragranular pyramidal neurons in monkey prefrontal cortex , 2001, The Journal of comparative neurology.
[95] L. Siever,et al. Magnetic resonance imaging of the thalamic mediodorsal nucleus and pulvinar in schizophrenia and schizotypal personality disorder. , 2001, Archives of general psychiatry.
[96] A. Sampson,et al. GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. , 2001, The American journal of psychiatry.
[97] Pat Levitt,et al. Molecular Characterization of Schizophrenia Viewed by Microarray Analysis of Gene Expression in Prefrontal Cortex , 2000, Neuron.
[98] R. Hoffman,et al. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. , 2000, Archives of general psychiatry.
[99] A. Sampson,et al. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. , 2000, Archives of general psychiatry.
[100] P. Goldman-Rakic,et al. Destruction and Creation of Spatial Tuning by Disinhibition: GABAA Blockade of Prefrontal Cortical Neurons Engaged by Working Memory , 2000, The Journal of Neuroscience.
[101] A. Sampson,et al. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. , 1999, The American journal of psychiatry.
[102] A Reichenberg,et al. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. , 1999, The American journal of psychiatry.
[103] P. McKenna,et al. Measurement of GABAergic parameters in the prefrontal cortex in schizophrenia: focus on GABA content, GABAA receptor α-1 subunit messenger RNA and human GABA transporter-1 (hGAT-1) messenger RNA expression , 1999, Neuroscience.
[104] G. Gigerenzer,et al. Specific attentional dysfunction in adults following early start of cannabis use , 1999, Psychopharmacology.
[105] P. Goldman-Rakic,et al. The reduced neuropil hypothesis: a circuit based model of schizophrenia , 1999, Biological Psychiatry.
[106] Vann Bennett,et al. AnkyrinG Is Required for Clustering of Voltage-gated Na Channels at Axon Initial Segments and for Normal Action Potential Firing , 1998, The Journal of cell biology.
[107] S. Hirsch,et al. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia , 1998, Journal of neurology, neurosurgery, and psychiatry.
[108] B. Moghaddam,et al. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.
[109] Philip D. Harvey,et al. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. , 1998, The American journal of psychiatry.
[110] T. Woo,et al. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[111] P. Goldman-Rakic,et al. Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. , 1998, Archives of general psychiatry.
[112] K. Davis,et al. Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. , 1997, Archives of general psychiatry.
[113] P. Huttenlocher,et al. Regional differences in synaptogenesis in human cerebral cortex , 1997, The Journal of comparative neurology.
[114] L. Glantz,et al. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity. , 1997, Archives of general psychiatry.
[115] D. Piomelli,et al. A second endogenous cannabinoid that modulates long-term potentiation , 1997, Nature.
[116] T. Woo,et al. Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. , 1997, The American journal of psychiatry.
[117] M. Iyo,et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET , 1997, Nature.
[118] N. Perrone-Bizzozero,et al. Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[119] P. Somogyi,et al. Differential synaptic localization of two major gamma-aminobutyric acid type A receptor alpha subunits on hippocampal pyramidal cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[120] Michael F. Green,et al. What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.
[121] B. Moghaddam,et al. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[122] D. Rosenberg,et al. Postnatal maturation of the dopaminergic innervation of monkey prefrontal and motor cortices: A tyrosine hydroxylase immunohistochemical analysis , 1995, The Journal of comparative neurology.
[123] J. S. Lund,et al. Synchronous development of pyramidal neuron dendritic spines and parvalbumin-immunoreactive chandelier neuron axon terminals in layer III of monkey prefrontal cortex , 1995, Neuroscience.
[124] E. G. Jones,et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. , 1995, Archives of general psychiatry.
[125] Jane S. Paulsen,et al. Neuropsychological deficits in schizophrenics. Relationship to age, chronicity, and dementia. , 1994, Archives of General Psychiatry.
[126] Françoise Condé,et al. Local circuit neurons immunoreactive for calretinin, calbindin D‐28k or parvalbumin in monkey prefronatal cortex: Distribution and morphology , 1994, The Journal of comparative neurology.
[127] J. Krystal,et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.
[128] R. Gur,et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. , 1994, Archives of general psychiatry.
[129] D. Javitt,et al. Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.
[130] D. Pickar,et al. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. , 1991, Archives of general psychiatry.
[131] B. Bogerts,et al. A morphometric study of the dopamine-containing cell groups in the mesencephalon of normals, Parkinson patients, and schizophrenics. , 1983, Biological psychiatry.
[132] D. Kavanagh,et al. Substance Misuse in Patients with Schizophrenia , 2012, Drugs.
[133] Wei Zhang,et al. Reduced Dendritic Spine Density in Auditory Cortex of Subjects with Schizophrenia , 2009, Neuropsychopharmacology.
[134] Nitin Gogtay,et al. Brain Neuroplasticity in Healthy, Hyperactive and Psychotic Children: Insights from Neuroimaging , 2008, Neuropsychopharmacology.
[135] D. Lewis,et al. Neuroplasticity of Neocortical Circuits in Schizophrenia , 2008, Neuropsychopharmacology.
[136] T. Insel,et al. Cure therapeutics and strategic prevention: raising the bar for mental health research , 2006, Molecular Psychiatry.
[137] David A Lewis,et al. GABA Targets for the Treatment of Cognitive Dysfunction in Schizophrenia. , 2005, Current neuropharmacology.
[138] C. Carter,et al. A specific deficit in context processing in the unaffected siblings of patients with schizophrenia. , 2003, Archives of general psychiatry.
[139] William Byne,et al. Postmortem assessment of thalamic nuclear volumes in subjects with schizophrenia. , 2002, The American journal of psychiatry.
[140] B. Pakkenberg,et al. No deficit in total number of neurons in the prefrontal cortex in schizophrenics. , 2001, Journal of psychiatric research.
[141] D. Lewis,et al. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. , 2000, Archives of general psychiatry.
[142] T. Goldberg,et al. Cognitive impairment in schizophrenia is the core of the disorder. , 2000, Critical reviews in neurobiology.
[143] Karl J. Friston,et al. Schizophrenia: a disconnection syndrome? , 1995, Clinical neuroscience.
[144] P S Goldman-Rakic,et al. Synaptogenesis in the prefrontal cortex of rhesus monkeys. , 1994, Cerebral cortex.